IP Library Granted Patent US 7,968,603
Granted Patent B2
US 7,968,603 · App. 12/228,100 · Granted Jun 28, 2011

Solid forms of selective androgen receptor modulators

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,968,603
App. No.
12/228,100
Granted
Jun 28, 2011
Kind
B2
Abstract

The present invention relates to solid forms of (S)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide and process for producing the same.

Claims (8)

1. A crystalline form (Form D) of (R) or (S)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide compound, characterized by:

a) an X-Ray Powder diffraction pattern comprising unique peaks at ° 2θ (d value Å) angles of about 4.4 (19.9), 8.5 (10.4), 8.8 (10.0), 11.3 (7.8), 12.7 (6.9), 13.8 (6.4), 14.4 (6.1), 14.6 (6.0), 15.1 (5.8), 16.1 (5.5), 16.6 (5.3), 16.9 (5.2), 18.0 (4.9), 18.7 (4.7), 19.0 (4.6), 19.4 (4.55), 20.8 (4.25), 22.1 (4.0), 22.7 (3.9), 23.1 (3.8), 23.4 (3.8), 24.7 (3.6), 24.9 (3.56), 25.3 (3.51), 27.8 (3.2), 29.3 (3.0); and

b) a melting point of about 130° C.

2. The crystalline form of claim 1 , whereby said crystalline form is characterized by an X-ray diffraction pattern as depicted in FIG. 18 .

3. A process for the preparation of crystalline form D of (R) or (S)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide of claim 1 , said process comprising mixing amorphous (R) or (S)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide in solvent/antisolvent mixture at a temperature of about 50° C. under conditions permissive to crystallization, thereby obtaining said crystalline form.

4. The process of claim 3 , wherein said solvent/antisolvent is ethyl acetate/cyclohexane mixture.

5. A solid composition comprising crystalline form D of (R) or (S)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide compound of claim 1 and a suitable carrier or diluent.

6. The crystalline form of claim 1 , whereby said crystalline form is characterized by an X-ray diffraction pattern as containing the unique identification peaks at ° 2θ (d value Å) angles of about 4.4 (19.9), 8.8 (10.0), 11.3 (7.8), and 13.8 (6.4).

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2020
From: ONCTERNAL THERAPEUTICS, INC.
To: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
Reel/Frame 054318/0958 →
CHANGE OF NAME Recorded Jul 4, 2019
From: GTX, INC.
To: ONCTERNAL THERAPEUTICS, INC
Reel/Frame 049679/0298 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2011
From: DALTON, JAMES T.; DICKASON, DAVID A.; HONG, SEOUNG-SOO; BIRD, THOMAS G.; AHN, TAI
To: GTX, INC.
Reel/Frame 027244/0110 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 17, 2010
From: DALTON, JAMES T.; DICKASON, DAVID A.; HONG, SEOUNG-SOO; BIRD, THOMAS G.; AHN, TAI
To: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
Reel/Frame 025003/0369 →